Germany’s Merck to Acquire Silence Therapeutics in $1.3 Billion Deal
The deal adds siRNA technology and closes in Q1 2027.
The deal adds siRNA technology and closes in Q1 2027.
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.